Acute Heart Failure Syndromes: The Role of Vasopressin Antagonists

References

• Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53: 557–73
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82: 1724–9
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46: 1785–91
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006; 119(Suppl 1)S3–S10
   Google Scholar
• Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003; 4(Suppl 7)S21–30
   Google Scholar
• Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006; 97: 1064–7
   PubMed Web of Science ®Google Scholar
• Yamokoski LM, Hasselblad V, Moser DK, Binanay C, Conway GA, Glotzer JM, et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J Card Fail. 2007; 13: 8–13
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980–8
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167: 1998–2005
   PubMed Web of Science ®Google Scholar
• Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. 2008; 5: 91–6
   Google Scholar
• Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M. Hyponatremia in heart failure. Heart Fail Rev. 2009; 14: 59–63
   PubMed Web of Science ®Google Scholar
• Filippatos G, Parissis JT. Vasopressin antagonists for the treatment of acute decompensated heart failure: When, for whom, for how long, and on what standard therapy?. J Card Fail. 2008; 14: 648–50
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417–23
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52: 1540–5
   PubMed Web of Science ®Google Scholar
• Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006; 91: 2145–52
   PubMed Web of Science ®Google Scholar
• Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007; 27: 447–57
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099–112
   PubMed Web of Science ®Google Scholar
• Gheorghiade, M, Gattis, WA, O'Connor, CM, Adams, KF,Jr, Elkayam, U, Barbagelata, A, , et al Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004;291:1963–71.
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007; 49: 2151–9
   PubMed Web of Science ®Google Scholar
• Konstam, MA, Gheorghiade, M, Burnett, JC,Jr, Grinfeld, L, Maggioni, AP, Swedberg, K, , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319–31.
   PubMed Web of Science ®Google Scholar
• Gheorghiade, M, Konstam, MA, Burnett, JC,Jr, Grinfeld, L, Maggioni, AP, Swedberg, K, , et al Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332–43.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: A dose-ranging pilot study. J Card Fail. 2008; 14: 641–7
   PubMed Web of Science ®Google Scholar